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TBARS tiobarbituric acid reactive substances 
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4. Introduction 
4.1 Preeclampsia 
Preeclampsia is a pregnancy-specific disorder defined clinically as de novo 
hypertension and proteinuria occurring after 20 weeks’ gestation. Preeclampsia is a common 
complication in the second half of pregnancy and is potentially dangerous to both mother 
and fetus. It is the most important cause of maternal death in Scandinavia, Iceland, Finland, 
United Kingdom and the USA (1-3), and the incidence of preeclampsia has remained stable 
for the last fifty years. Preeclampsia occurs in 3-10% of pregnancies, and approximately 
50 000 women worldwide die from this disease every year (4). In addition, the mortality of 
the offspring of a preeclamptic mother is also increased (5). In Norway, the most recent 
survey (2004) from the Medical Birth Registry of Norway (MBRN) reported an incidence of 
3.7% (6). 
The pathogenesis of preeclampsia is not fully understood. Considerable research 
over more than five decades has led to the notion of preeclampsia as a multifactorial 
syndrome with maternal and fetal interaction, with the participation of two genetically 
different individuals (7). 
4.1.1  Definitions 
There is no global agreement regarding the definition of preeclampsia or other 
hypertensive disorders in pregnancy. The clinical criteria of de novo hypertension and 
proteinuria are still the most generally accepted. According to the National High Blood 
Pressure Education Program Working Group on High Blood Pressure in Pregnancy (8), the 
following classifications are recommended and have been used in this PhD thesis:  
Preeclampsia: A syndrome defined by hypertension and proteinuria. Hypertension is 
defined as a systolic blood pressure level of 140 mm Hg or higher or a diastolic blood 
pressure level of 90 mm Hg or higher occurring after 20 weeks’ gestation in a woman with 
previously normal blood pressure. Proteinuria is defined as urinary excretion of 0.3 g 
protein or higher in a 24-hour urine specimen (or protein dipstick reading equal to or higher 
than 1+ on more than one midstream urine sample six hours apart).
Eclampsia: The occurrence of seizures in a preeclamptic woman, where the seizures cannot 
be attributed to other causes.
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Gestational hypertension: Blood pressure elevation without proteinuria developing in a 
woman after 20 weeks’ gestation, with blood pressure levels returning to normal 
postpartum. 
Chronic hypertension: Hypertension that is observable before pregnancy or before 20 
weeks’ gestation. Hypertension that is primarily diagnosed during pregnancy and which 
persists beyond the 42
nd
 day postpartum is also classified as chronic hypertension.  
Superimposed preeclampsia: Preeclampsia developing either on chronic hypertension or on
diabetes mellitus. 
4.1.2  Clinical picture of preeclampsia
Preeclampsia is a maternal syndrome, unpredictable both in its onset, progression 
and severity. The clinical picture ranges from mild, late onset preeclampsia (with no clinical 
signs of the disease other than elevated blood pressure and proteinuria) to severe, early-
onset preeclampsia, with maternal multiorgan failure, including disseminated intravascular 
coagulopathy (DIC), renal failure, cerebral hemorrhage and hepatic failure.  
The HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome is 
discussed as a variant of preeclampsia (9). Eclampsia, a life threatening, although rare 
complication of preeclampsia, includes convulsions. Additionally, there is an increased risk 
of abruption of the placenta, a life-threatening situation for both mother and fetus (10). 
Other effects on the fetus include health consequences resulting from iatrogen premature 
delivery, such as neonatal death, persistent bronchopulmonal dysplasia, as well as placental 
insufficiency with consequent fetal growth restriction (11;12).
4.1.3  Risk factors for preeclampsia
Numerous maternal factors can predispose women to the syndrome, including 
genetic (13), behavioral or environmental factors. Some of the predisposing factors include 
diabetes mellitus (14), increased insulin resistance (14), hypertension (8), black race (15), 
and high body mass index (BMI) (15). Pregnancies with large placentas (as in twin 
pregnancies, diabetic pregnancies and hydatidiform moles), primigravidas, and a previous 
pregnancy with preeclampsia (16), increase the risk of developing preeclampsia. A new 
sexual partner and the use of barrier contraception are both associated with an increased risk 
of developing preeclampsia, whereas previous antigen exposure is protective (17). There are 
also reports of family clustering of preeclampsia (18;19), although no general, world wide 
genetic explanation has been confirmed. Skjærven et al (20), analyzing data from the 
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MBRN, found that the protective effect of a previous pregnancy against preeclampsia was 
associated with the time between the pregnancies, and probably not the paternal antigen 
exposure itself. 
4.1.4 Preeclampsia and implications for health later in life 
It has been proposed that pregnancy could be viewed as “a medical stress-test for 
life” (21). According to this concept, the increased physiological demands on the pregnant 
women in some cases are not met, resulting in gestational syndromes such as gestational 
hypertension and preeclampsia. The immediate remission is delivery of the baby, but in the 
long-term the problems reappear in the mother, especially with advancing age, as the 
reserves of the already “primed” organs diminish. If a pregnant woman does not develop 
gestational syndromes during her pregnancy, she is in a privileged position with a reduced 
risk of developing several diseases later in life as compared to a pregnant woman with a 
gestational syndrome (21). 
 There are several studies reporting increased maternal risk of cardiovascular disease 
later in life after a pregnancy with hypertensive disorders, including preeclampsia (5;22-25). 
In a long-term follow-up study by Irgens et al (5), including data from the MBRN, an 
eightfold elevated risk of dying from cardiovascular disease and a fivefold elevated risk of 
dying from stroke was found in women with preterm delivery and preeclampsia. A study by 
Smith et al (26) of 130 000 Scottish women who had developed cardiovascular disease 
(CVD), demonstrated a twofold risk of developing CVD later in life following a history of 
preeclampsia, as well as a sevenfold risk of CVD following preeclampsia and delivery of a 
baby below 2.5 kilos.
In addition, long-term effects for individuals exposed to an intrauterine preeclamptic 
environment are being increasingly studied. It seems that the offspring of preeclamptic 
mothers have an increased risk of adolescent hypertension (27;28), as well as a decreased 
risk of breast cancer (29), but the mechanisms are still unknown (30).
4.1.5    Treatment and prevention of preeclampsia  
 Preeclampsia is curable only by termination of the pregnancy and removal of the 
placental tissue. If parts of the placenta are retained after delivery of the baby, preeclampsia 
can persist (31). Symptomatic treatment with antihypertensive medication may prolong the 
pregnancy and reduce cerebral hemorrhagic episodes, but no other positive effects on 
maternal and fetal outcome have been documented (32). Glucocorticoids are administered to 
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women with threatening premature delivery prior to 34 weeks’ gestation, including 
preeclamptic women. Glucocorticoids enhance fetal lung maturation and thereby reduce 
fetal mortality and morbidity. However, this treatment has no documented positive effect on 
the pregnant women (33). 
As the etiology of preeclampsia is still unknown, and probably also multi-factorial, 
prevention of the disease is not yet within reach. Various approaches to preventing 
preeclampsia have been tried. Prophylactic treatment with aspirin has been shown to reduce 
the risk of preeclampsia by 19%, but there is still uncertainty as to which groups of pregnant 
women would benefit from such preventional therapy (34). Thus, there is still considerable 
controversy about the use of aspirin for prevention of preeclampsia (35;36). The Magpie Trial 
(37) reported that treatment with Magnesium sulphate in women with preeclampsia reduces 
the risk of eclampsia by 50% and probably also reduces the risk of maternal death.  
 There are a number of treatment and prevention- studies where results are less clear. 
Antioxidant supplementation, using vitamins E and C, has been shown to reduce the 
frequency of preeclampsia in a high-risk population (38;39). However, this effect was not 
verified in a randomized, multi-center trial recently published by Poston et al (40). On the 
contrary, the Poston study reported that the vitamin-treated group had more low birth 
neonates (<2500 grammes) than the non-vitamin treated group (28% versus 24% 
respectively), an increased need for neonatal intensive care and a higher incidence of stillbirth 
(1% versus 0.5%). In the Poston-study, the vitamin-treated group also had an increased risk of 
gestational hypertension and an increased need for MgSo4 and antihypertension treatment. 
The objection has been raised that the randomization of the patients in the study was too late 
in pregnancy and that the early damage caused by oxidative stress may be an early and 
irreversible event of pregnancy. It has therefore been hypothesized that earlier antioxidant 
intervention might have a positive effect (40). In light of the disappointing results to date of 
using antioxidants to prevent preeclampsia, this underlines the importance of evaluating both 
maternal and fetal outcome in intervention studies as well as markers of oxidative stress and 
antioxidants. It also highlights the importance of treating maternal complications and fetal 
outcome, rather than simply diagnosing preeclampsia (41).  
 Studies on calcium supplementation as a mean of preventing preeclampsia have 
shown this to be generally ineffective. It might possibly be effective in developing 
countries, however, where nutrition for pregnant women may be inadequate (42).   
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Finally, earlier observational studies have suggested a potential role for omega-3-
fatty acids in decreasing the incidence of preeclampsia. This has not been confirmed in 
randomized, prospective trials, however (43).    
4.1.6  Preeclampsia and defect placentation 
 A successful implantation is the end result of complex molecular interactions 
between the hormonally primed uterine endometrium and the mature blastocyst (44). The 
function of the uteroplacental unit is to secure an adequate exchange of nutrients, gases and 
metabolic end products. These functions are mediated by increased blood flow through the 
uterus. During the early phase of placental development, extravillous cytotrophoblasts 
(stemming from the outer cell-layer of the blastocyst) stream out of the anchoring villi, 
penetrating the syncytiotrophoblast layer, entering the decidua and invading and 
transforming the maternal spiral arteries. The major structural alterations occurring in these 
spiral arteries in early pregnancy (so-called “physiological changes”) normally transform 
the arteries to vascular channels outside maternal vascular control, allowing an increased 
maternal blood supply to the placenta (45) in the last part of the pregnancy (figure I). 
 Trophoblast invasion of the decidua and maternal myometrium is thought to be a 
key event in early placentation (46). Reduced trophoblast invasion may represent one of the 
basic defects leading to preeclampsia (47). 
This reduced invasion of extracellular 
trophoblast is followed by a shallow 
transformation of the spiral arteries (46), 
leaving them narrow, tortuous and thick-
walled. Besides remaining non-transformed, 
the spiral arteries in preeclampsia can have 
areas of lipid deposition in the vessel wall, a 
phenomenon known as acute atherosis. The 
name was given to the changes, first 
observed in 1945, as a result of the 
morphological resemblance of early phases 
of atherosclerotic lesions in vessels (48).
Figure I: Schematic drawing of a term placental 
structure. The arrows represent blood flow from the 
decidual arteries into the intervillous spaces and back into the venous blood (modified after Junqueira LC et al. 
Basic Histology. Appleton and Lange 1989: 452-458). 
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There is still some controversy and insufficient knowledge regarding the etiology 
and molecular mechanisms behind the formation of acute atherosis. This is partly due to the 
difficulty in obtaining sufficient and adequate tissue from the placenta bed, as well as a lack 
of relevant animal models.  
Normal placental function relies on adequate maternal blood supply through the 
wholly or partially transformed spiral arteries in the placental bed (figure II). Any process 
that results in mural or occluding thrombi in these arteries reduces the flow and can lead to  
hypoxia and ischemia as well as infarcts in the placental tissue, i.e. reduced placental 
function, which is more common in preeclampsia than in uncomplicated pregnancies (49). 
A hypoxic placenta is believed to release toxic compounds to the maternal circulation, 
resulting in maternal endothelial dysfunction and oxidative stress (50;51). Acute atherosis in 
spiral arteries is associated with an increased risk of thrombosis and thereby placental 
ischemia and infarctions (49).  
Bearing in mind the multifactorial aspects of preeclampsia, defect placentation 
additionally seems to be related to immunological processes such as decreased trophoblast 
expression of human leucocyte antigen-G (HLA-G) (52), as well as interaction with 
maternal lymphocytes such as uterine natural killer (NK) cells (53).
4.1.7  Inflammation and endothelial dysfunction  
Endothelial cells represent a semipermeable barrier between the vessel wall and the 
blood flow in the vascular system (54). The endothelial lining plays a central role in the 
regulation of hemostasis via a series of receptors for proteins, hormones, lipid transports as 
well as through cell-cell interactions (55). “Endothelial dysfunction” has not been precisely 
defined, but the term is used to indicate change in endothelial properties with activation and 
abnormal function (56). Evidence suggests that endothelial activation and low grade 
maternal inflammation is present in all pregnancies, there being merely a different gradient 
in preeclampsia, with a stronger inflammatory response (57). The central pathological 
features of the maternal syndrome may thus include the presence of an excessive maternal 
inflammatory response, resulting in dysfunction, activation and peripheral vasoconstriction 
with reduced circulating volume, which in turn leads to oxidative stress (57).
4.1.8  Preeclampsia and the two-stage-model 
The present concept of the pathogenesis of preeclampsia involves a two-stage model (figure 
II). Stage 1 refers to a defect and reduced trophoblast invasion into the maternal spiral 
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arteries (with reduced physiological arterial changes or remodeling) leading to reduced 
placental perfusion. Stage 2 refers to a generalized dysfunction and activation of the 
endothelium, and, finally, development of the maternal syndrome (58;59). Several factors 
have been proposed as the link between the two stages of preeclampsia. Among the 
substances suggested as being freed from the placenta to the maternal circulation are 
syncytiotrophoblast debris (60), oxidized lipids (61) and angiogenic factors (62-64).  
Recently, angiogenic associated factors, such as placental sFlt1 (soluble fms-like tyrosine 
kinase 1) (65) and soluble endoglin (66), have been proposed as possible circulating 
endothelial damaging factors originating in a hypoxic placenta in preeclampsia. 
Figure II. Poor placentation and preeclampsia (Redman C & Sargent I. Science 2005;308:1592-4). 
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4.1.9  Oxidative stress in preeclampsia 
Oxidative stress is defined as a biochemical imbalance between free radical damage 
and antioxidant protection. It arises from excessive generation of free radicals and/or 
inadequate endogenous antioxidant capacity (67;68). Reactive oxygen species (ROS) are 
constantly produced as by-products of normal oxidative metabolism in mitochondria and 
other cellular reactions (69;70). All organisms possess a range of enzymatic and non-
enzymatic antioxidant systems, which serve to protect against the harmful oxidative 
reactions that occur as a consequence of this endogenous ROS production. Examples of 
antioxidant enzymes are superoxide dismutase, gluthatione reductase and catalase; examples 
of non-enzymatic antioxidants are vitamin C, vitamin E, vitamin A, glutathione and 
flavenoids (71). Under certain conditions, an increase in oxidants and a decrease in 
antioxidants cannot be prevented, and the oxidant/ antioxidant balance shifts towards the 
oxidative state. This may result in oxidative stress, which is implicated as a factor 
contributing to the endothelial dysfunction and pathological changes in preeclampsia (72-
74).
Pregnancy itself is a condition of increased oxidative stress (75), and may contribute 
to endothelial dysfunction and the clinical development of preeclampsia (76;77). There is 
considerable evidence supporting an increase in products of oxidative stress in women with 
preeclampsia, demonstrated both in the placenta (61;78) and in maternal peripheral blood 
cells (73), as well as in the maternal circulation (79). There is still some controversy with 
respect to the results for latter compartment (80;81). 
 A number of circulating compounds may under certain circumstances enhance 
oxidative stress. They include lipoproteins, lipids, proteins, glucose and advanced glycation 
end products (AGEs). 
An established method for measuring the end products of increased oxidative stress 
is to measure the degree of lipid peroxidation. Lipid peroxidation occurs when ROS interact 
with polyunsaturated fatty acids in membranes or lipoproteins (82). In preeclampsia, there is 
development of excessive maternal hyperlipidemia, and especially hypertriglyceridemia, as 
compared to normal pregnancy (83;84) and these changes are present long before the onset 
of preeclampsia (85). Oxidation of low density lipoproteins, which are prominent in 
preeclampsia, is one example of the measurable consequences of increased oxidative stress 
(86). There are several methods of examining lipid peroxidation products in biological 
samples, but most of them have both low specificity and low sensitivity in terms of 
measuring changes in free radical status. Among such lipid peroxidation products are the 
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tiobarbituric acid reactive substances (TBARS), lipid hydroperoxides and the isoprostanes 
(87-89).   
 There are also end products of oxidative stress, other than lipid peroxidation 
products, that can be measured as indices of oxidative stress. Direct damage to proteins by 
peroxidation of the amino acids can also give rise to protein carbonyls, which may serve as 
more general biomarkers of oxidative stress (90). Plasma protein carbonyls have been 
demonstrated to be elevated in preeclampsia as compared to controls (91).  
Peroxinitrate, produced by the vasorelaxant nitric oxide (NO) reacting with 
superoxide anions (produced under conditions of oxidative stress) is also a potential marker 
of oxidative stress. Peroxinitrite is regarded as a marker of “nitrative stress” which, 
subsequent to oxidative stress, is seen in the placenta in preeclampsia and diabetes in 
association with altered placental function (92). NO is produced by endothelial cells and is 
also known to react with superoxide anions (produced under conditions of oxidative stress), 
yielding peroxynitrite that may impair vascular function (93).
4.1.10  Angiogenic factors in preeclampsia 
Considerable attention has recently been focused on angiogenesis-related factors in 
the etiology of preeclampsia. It has been postulated that preeclampsia might be a syndrome 
of angiogenic disorders and that the angiogenic factor soluble fms-like tyrosine kinase 1 
(sFlt1) plays a causative role in the development of preeclampsia (65;94). PlGF (placental 
growth factor) and VEGF (vascular endothelial growth factor) are growth factors necessary 
for normal endothelial function, and also important factors in the vasculogenesis and 
angiogenesis of early placentation (95). Recently the anti-angiogenic factor sFlt1, which 
binds soluble VEGF and PlGF and inhibits their effect on the vascular endothelium, was 
found to be up-regulated in preeclamptic placentas (65). High serum levels of sFlt have been 
found in preeclampsia (64;65), and elevated serum concentrations of sFlt1in the second 
trimester may predict onset of preeclampsia (63). A recent Norwegian study also showed 
that a low rise of maternal PlGF and a high rise of sFlt1 between the first and second 
trimester are strong predictors of early onset preeclampsia (96). 
Recently, soluble endoglin (sEng) has been found in elevated concentrations in 
preeclamptic maternal serum (66). sEng cooperates with sFlt1 in inducing endothelial 
dysfunction in vitro, and severe preeclampsia-like illness can be induced in pregnant rats 
(65). sEng and sFlt1 block pro-angiogenic effects of TGF-E and VEGF in vitro, and show 
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additive effects, indicating that these soluble receptors may act in concert to cause 
endothelial dysfunction (66). 
4.2 Preeclampsia and fetal aspects 
The fetal well-being and development in utero during a pregnancy is dependent on 
both the fetal genes and the intrauterine environment. The in utero environment is mainly 
mediated through the placenta, which serves all the needs of the infant, including nutritional 
and oxygen supply, disposing of waste products as well as serving hormonal support for 
fetal growth and development. 
In pregnancies complicated with preeclampsia, the consequences for the fetus may 
be both those according to prematurity, like lack of lung maturation and growth restriction, 
as well as the long term consequences for the infant, like increased risk of developing 
cardiovascular disease, dying from stroke and developing hypertension in adulthood, as 
described in chapter 4.1.4.
Maternal endothelial dysfunction is believed to be the common final pathway 
leading to the syndrome of preeclampsia (50;51). As described above, a dominating 
hypothesis is that agents produced by the relatively hypoxic placenta are transferred to the 
maternal circulation, causing endothelial dysfunction. To what extent such placental agents 
could affect the fetus, or are present in the fetal circulation at increased concentrations in 
preeclampsia, has not been fully explored. Only a few studies have addressed this issue, 
with conflicting results (97-100).
Prematurity has been associated with increased oxidative stress (101-103), and 
oxidative stress has also been implicated in several of the diseases of prematurity such as 
bronchopulmonary dysplasia, intraventricular hemorrhage and necrotizing enterocolitis 
(103-106). 8-isoprostane, an acknowledged marker of oxidative stress, has been 
demonstrated elevated in plasma of preterm infants compared to term infants in only one 
study (107), and also low concentrations of antioxidants in the fetal circulation have been 
demonstrated, possibly representing infants more vulnerable to oxidative injury (108-110). 
Since preeclampsia is associated with increased oxidative stress both in the maternal 
circulation and in the placenta, it is of interest to explore whether this imbalance between 
pro-and antioxidants also is present in the circulation of an infant born to a preeclamptic 
mother.
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4.3 Diabetes mellitus and superimposed preeclampsia 
 Diabetes mellitus and preeclampsia share many pathophysiological features, 
including endothelial dysfunction, insulin resistance, oxidative stress, and inflammation 
(14;111;112). Both pre-gestational diabetes and gestational diabetes mellitus (GDM) are 
associated with a two to fourfold increased risk of developing preeclampsia in pregnancy 
(113-115), named superimposed preeclampsia. In this context, this includes women with 
diabetes mellitus (pre-existing or gestationally induced) with development of preeclampsia 
in the present pregnancy. The diagnosis of “superimposed preeclampsia” is also commonly 
used for women with pre-existing hypertension with a development of preeclampsia 
(development of proteinuria without hypertension induced nephropathy) after week 20 of 
pregnancy.
22
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5. Aims of Study
The main aim of the present thesis was to investigate the relationship between placental 
acute atherosis and maternal circulating oxidative stress. Both features are assumed to be 
essential in preeclamptic pregnancies, but their relationship has not been extensively 
studied. The presence of circulating oxidative stress in maternal preeclampsia has also been 
debated, and the fetal situation is mainly unexplored.  
Specifically, the aims were to:
1. evaluate histologically a new vacuum suction method designed to obtain decidual tissue 
from the placental bed, focusing on the yield of transformed decidual spiral arteries. We 
wanted to compare the tissue obtained by this method with two other well-established 
methods to obtain placental bed tissue, i.e. the placental bed biopsy method and the 
placental basal plate section method (Paper I) 
2. study the phenomenon of acute atherosis in preeclampsia and controls in the decidual 
tissue from the vacuum suction method (Paper IV) 
3. assess the maternal and fetal circulating levels of oxidative stress as well as antioxidant 
capacity in preeclamptic pregnancies, compared to uncomplicated pregnancies, using 8-
isoprostane, a well-known marker of oxidative stress, and antioxidant indices (Paper II 
and III) 
4. explore a potential correlation between maternal oxidative stress (measured as 8-
isoprostane) and the maternal serum concentration of the placenta-produced angiogenic 
factor sFlt1. 8-isoprostane and sFlt1 are excessively produced by preeclamptic placentas 
as compared to placentas from uncomplicated pregnancies (65), and an association 
between these factors in the maternal circulation has not been explored previously 
(Paper II) 
5. compare the presence of acute atherosis in decidual tissue spiral arteries, using our 
evaluated vacuum suction method, with the possible presence of hyperlipidemia and 
oxidative stress in the maternal circulation, both in uncomplicated and preeclamptic 
pregnancies (Paper IV). 
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6. Summary of Papers 
Paper I: “Evaluation of the decidual suction method” 
  In this methodology paper, we wanted to evaluate and compare tissue from the 
placental bed obtained by three different methods: decidual tissue from our cesarean section 
biobank study, sampled using our own vacuum suction method (n=51), compared with 
archive material from placental bed biopsies (PBB, n=33) and placental basal plate sections 
(BPS, n=33). The success rate was defined as the proportion of cases in which one random 
tissue section contained at least one transformed decidual spiral artery with interstitial 
trophoblasts. The success rate of the decidual suction method (86%) was superior to the two 
other methods, the PBB method (61%) and the BPS method (48%). We also documented 
that the vacuum suction method was safe for the patient, both in the short-term and long- 
term. 
Paper II: “Maternal oxidative stress in preeclampsia” 
Our cesarean section biobank at Ullevål University Hospital was used for this study, 
including 21 women with preeclampsia and 38 women with uncomplicated pregnancies.  
Evidence of increased oxidative stress, as assessed by a 62% elevated median 8-
isoprostane concentration, was found in maternal circulation in the group of preeclamptic 
women compared to the group of women with uncomplicated pregnancies (median 
concentrations 354 pg/mL vs 218 pg/mL, P=0.02). For the total antioxidant capacity, 
measured as FRAP (ferric reducing ability of plasma), median concentration was 26% 
higher in the preeclampsia group as compared to the uncomplicated pregnancy group, 
demonstrating a relatively greater increase in oxidative stress (measured as 8-isoprostane) 
than in antioxidant capacity (measured as FRAP) in the maternal circulation in 
preeclampsia. The d-ROM (diacron reactive oxygen metabolites) test, another index of 
oxidative stress, did not show statistical significant differences between the control group 
and the preeclampsia group (457 Carr U vs 550 Carr U, P=0.06), and no difference in 
vitamin E levels was demonstrated between the control group and the preeclampsia group 
(35.8 μmol/L vs 35.8 μmol/L, P=0.7).  We were also able to demonstrate a positive 
correlation between maternal angiogenic factor sFlt1 and maternal 8-isoprostane 
concentrations in the preeclampsia group (Spearman correlation 0.5, P=0.03).  
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Paper III: “Oxidative stress and antioxidant status in fetal circulation in 
preeclampsia”
Our cesarean section biobank at Ullevål University Hospital was also used for this 
study, including 19 women with preeclampsia (the same patient population used in Paper II, 
except for two extra patients included in Paper II) and 33 controls (the same patient 
population used in Paper II, except for five extra patients included in Paper II).
We demonstrated no statistical significant difference in median concentration of 8-
isoprostane between the preeclampsia group and control group either in the umbilical vein 
(955 pg/mL vs 780 pg/mL, P=0.41) or in the umbilical artery (233 pg/mL vs 276 pg/mL, 
P=0.65), indicating no evidence of increased oxidative stress in fetal circulation in 
preeclampsia, as evaluated by 8-isoprostane concentrations. Concentration of 8-isoprostane 
was significantly higher in plasma from the umbilical vein than artery, suggesting the 
placenta as the source of fetal circulating 8-isoprostane. Fetal and maternal concentrations 
of 8-isoprostane (from Paper II) did not correlate, neither for the preeclampsia nor for the 
control group.
For the total antioxidant capacity, measured as FRAP, median concentration was 
higher in preeclampsia than in controls, both in the umbilical vein and artery. Also, there 
was a statistical significant positive correlation between fetal and maternal FRAP values. 
For the preeclampsia group we demonstrated higher median vitamin E concentration in the 
umbilical vein compared to controls (5.7 μmol/L vs 3.6 μmol/L, P=0.001), but no difference 
between preeclampsia and controls was found in the umbilical artery (4.7 μmol/L vs 3.7 
μmol/L, P=0.19). In the umbilical artery, median vitamin E concentration was 
approximately 10% of maternal value. Fetal and maternal concentrations did not correlate 
(for either umbilical artery or vein), neither in preeclampsia nor controls. 
Paper IV: “Association between maternal oxidative stress and decidual acute 
atherosis”
Our cesarean section biobank at Ullevål University Hospital was again used for this 
study, including 49 women with preeclampsia (21 also used in Paper II and 19 used in Paper 
III), 46 controls (38 also used in Paper II and 33 used in Paper III) and 7 women with 
superimposed preeclampsia.
We demonstrated acute atherosis (defined as presence of CD68 positive foam cells 
and fibrinoid necrosis in the spiral artery wall) in 42% of the tissue from the preeclamptic 
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patients with identified spiral arteries. In addition, we demonstrated CD68 positive foam 
cells with fibrinoid replacement in 14% of the uncomplicated pregnancies. 
Our study did not show any association between the presence of acute atherosis in 
decidual spiral arteries and elevated oxidative stress (assessed by an elevated 8-isoprostane 
concentration) or dyslipidemia (assessed by triglyceride, HDL-Cholesterol and total 
cholesterol) in the maternal circulation of the preeclampsia group.  
We demonstrated elevated concentrations of 8-isoprostane in the maternal 
circulation of the diabetes group with superimposed preeclampsia compared to both the 
control group (691 pg/mL vs 218 pg/mL, P=0.03) and the preeclampsia group (691pg/mL 
vs 354 pg/mL, P=0.14). The group of patients with diabetes mellitus and superimposed 
preeclampsia is small (n=7) and the results thus need to be interpreted with caution. The 
study needs to be repeated with a larger patient cohort.
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7. General Discussion 
7.1 Subjects included 
            The patients included in the four papers of this PhD thesis were recruited at the 
Department of Obstetrics, Ullevål University Hospital, Norway. As well as being the largest 
general and referral hospital in Norway, it also has the largest delivery unit, with 
approximately 6500 deliveries per year. This represents 12% of all deliveries in Norway. 
The incidence of preeclampsia in the Ullevål population is 6.9% as opposed to 3.7% in the 
Norwegian population as a whole (6). Twenty-two percent of the preeclampsia patients are 
delivered by the cesarean route at our Department.  
The recruitment of patients for our biobank study started in March 2001. All the 
patients in Papers I-IV are part of this ongoing biobank study, apart from the 33 subjects 
(Paper I) for whom placental bed biopsies and placental basal plate sections were taken 
from the archive routine diagnostic material from the Department of Pathology, Ullevål 
University Hospital. The biobank study includes women with uncomplicated as well as 
complicated pregnancies, the latter group comprising preeclamptic pregnancies and 
pregnancies complicated with diabetes mellitus.  
The preeclampsia patients included were previously healthy women who were 
delivered by cesarean section because vaginal delivery was not considered appropriate due 
to disease progression and/or unfavorable cervical ripening. They were all normotensive 
prior to pregnancy. Controls were healthy, normotensive women undergoing cesarean 
section due to breech presentation or for psychosocial reasons. In Paper IV we included a 
small group of diabetes mellitus patients with superimposed preeclampsia (n=7), in addition 
to the preeclampsia group and the control group. This group of patients with superimposed 
preeclampsia was delivered by the cesarean route with the same clinical indications as the 
remaining preeclampsia group. 
The time-consuming procedure of recruitment, collection and preparation of the 
biological material was principally performed by the two PhD students involved in the 
biobank study (Braekke and Harsem), both senior clinicians in their fields (pediatrics and 
gynecology/obstetrics, respectively). The patients were recruited mostly during the daytime, 
rarely on weekends and not during the summer or other holidays. It would have been 
preferable to include all patients delivered by cesarean section with a clinically verified 
diagnosis of preeclampsia during this study period. However, we do not believe the time-
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point random selection of pregnancies included would have significantly biased patient 
selection.
Due to the composition of patient population at Ullevål University Hospital, the 
biobank material consists of a subgroup of more severe preeclamptic patients than normally 
distributed in the Norwegian population. As the clinically less severe preeclampsia patients 
had vaginal deliveries, our group of preeclamptic patients has more severe preeclampsia 
(and deliveries at a lower gestational age) than the total preeclampsia group at the hospital. 
Our preeclampsia group is therefore not representative of all women with preeclampsia, but 
is possibly the biologically most interesting preeclampsia group to study, as early and severe 
preeclampsia have most severe consequences for the infant.
All patients included had a clinical indication for cesarean section. Of the eligible 
women asked to participate in the biobank study, only three refused; one in the preeclampsia 
group and two in the control group. The majority of the pregnant women included in our 
studies are Caucasian Norwegian (90%), the remainder are non-Western immigrants from 
Pakistan, Somalia and India.  
Since the biobank collection is ongoing, the numbers of patients included in the 
different studies (Papers I-IV) varies, depending on the number of patient samples available 
at the start of the various studies
 In Paper I, we compared the spiral artery findings in the decidual tissue (n=51) from 
our biobank study with archive paraffin-embedded tissue material from the basal plate 
(n=33), as well as from the placental bed (n=33), retrieved from the files in the Department 
of Pathology. The sections were evaluated morphologically and immunohistochemically by 
two observers, Harsem and Roald, the latter a senior pathologist. Only anecdotal clinical 
information was available, but this is of no significance in our methodological study. 
 In Paper II we included 21 patients with preeclampsia and 38 controls. These 
patients are also part of the patient populations in Paper III and IV. The number of patients 
is higher in the latter paper because of additional patients being recruited at the start of these 
studies. The number of patients in Paper III is somewhat smaller because of technically 
difficulties in collecting samples from all compartments from the same pregnancy, 
especially lack of fetal samples. These technical difficulties include situations were the 
operating doctor forgot to clamp the umbilical cord according to the protocol as well as 
limited umbilical cord blood volume in the premature pregnancies. 
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Variations in oxidative stress during labor in vaginal deliveries could have affected 
the results in Papers II-IV. We thus believe cesarean section was a preferable delivery mode 
for answering the main question of the studies: What is the relationship between placental 
acute atherosis and maternal circulating oxidative stress? We consider our decision to 
include only patients undergoing cesarean section as a strength of our study, since vaginal 
delivery is associated with oxidant stress (75). Increased oxidative stress has also been 
demonstrated in the fetal circulation after vaginal delivery, both measured as augmented 
lipid peroxidation products (116) and gluthatione (117). Additionally, as shown in Paper I, it 
would not have been possible to collect adequate decidual tissue from the retroplacental area 
after a vaginal delivery. A blind curettage procedure following vaginal delivery was 
considered unethical, as it is a clinically unnecessary procedure with a risk of uterine 
perforation. In Paper I we examined the risk of complications after the vacuum suction 
procedure from the placental bed during cesarean section; the method was proven safe both 
in a short-term and long-term perspective.  
A major advantage of our biobank selection is the quality of tissue material. This has 
been verified as non-degraded by mRNA studies and verified as site-relevant for the 
placental bed by histology (118). The bank also includes blood samples from the mother and 
fetus (umbilical cord) and extensive clinical information. All clinical information was 
personally and comprehensively collected from each patient by Harsem and Braekke, as 
well as from the medical chart and a national compulsory individual pregnancy chart 
following each pregnant woman in Norway. We therefore feel confident that the clinical 
information about the patients included is correct, and that the quality of the decidual tissue 
is not hampered due to time delay and poor tissue conservation. 
Another advantage of our biobank study concept is the possibility of doing long-term 
follow-up studies related to maternal and fetal morbidity, as patients have consented to 
being contacted with regard to participation in future studies. The biobank material is also 
valuable for further studies relating to the etiology and pathophysiology of preeclampsia. As 
there is still uncertainty as to which organ or tissues play the primary pathogenetic role in 
preeclampsia, the sampling from different tissues and compartments could be beneficial for 
further research. In our comprehensive biobank we have also included a skeletal muscle and 
fat tissue from the mother, as well as amniotic fluid samples and fetal cord blood sampled 
separately from umbilical vein and umbilical artery blood, allowing fetal-maternal 
comparisons (64;99;118). The possibility of feto-maternal comparison was one of the 
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primary ideas of the biobank, and other feto-maternal results have also been published from 
our group (64;99;118;119). 
Gestational length
One of the disadvantages of our study design is the lack of matching for gestational 
age. Since most of our preeclamptic patients have a severe disease, they are delivered early 
in gestation, as a result of disease progression. Our control group, however, consists of 
pregnant women delivered by cesarean section near term due to breech presentation or 
repeated cesarean section. It is clinically impossible to match the preterm preeclamptic 
cesarean delivered group with a prematurely delivered “control” group, since there would be 
extremely few clinical indications for a preterm cesarean delivery in uncomplicated 
pregnancies. Also, collection of umbilical cord blood with cordocentesis, in gestationally 
matched “controls”, would not be ethically acceptable for research purposes only. 
The gestational length and implications for interpretation of the results from the 
various analyses in this thesis are discussed in the method section. The gestational length of 
the study groups was not considered in Paper I, since this information and the diagnoses of 
the patients included were not known for the placental bed biopsies and placental basal plate 
sections, and the primary goal of the study was to compare the quality of the collected 
material, not considering the findings in accordance with clinical data. 
We found only one study demonstrating an inverse correlation between gestational 
length and concentrations of umbilical vein plasma free-F2-isoprostanes, with higher levels 
in the premature deliveries (120). According to this publication, we could therefore have 
expected higher levels of total 8-isoprostane in the infants from preeclamptic pregnancies as 
compared to controls, due to their lower gestational length, but no such correlation was 
found, when analyzing the whole study group together or the preeclampsia group alone, 
neither in the umbilical vein nor in the artery.
Severity of disease 
The most common ways of defining preeclampsia severity are either according to 
gestational length at delivery (severe preeclampsia: delivery prior to gestational week 34) or 
according to blood pressure level (systolic blood pressure level above 160 mm Hg as well as 
degree of proteinuria) (8). 
In our biobank studies and in this thesis, the majority of patients included have 
severe preeclampsia, defined both according to gestational length and according to elevated 
blood pressure. 
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  The severity of disease, as assessed according to the different analyses in the studies, 
is discussed further in the method section below. The differentiation of patient groups 
according to severity of disease was considered in Paper II, III and IV. In Paper I we 
included no information about gestational length and diagnoses.
7.2 Decidual tissue sampling and evaluation of acute atherosis
7.2.1  Tissue sampling 
The collection of the decidual material was performed using the method originally 
devised by principal supervisor Staff and her collaborators (121). In this biobank study, the 
vacuum suction procedure was performed by a limited number of operating gynecologists. 
The localization of the placenta was known preoperatively from ultrasound findings and 
manual palpation, and a careful vacuum suction was performed on the entire uterine wall 
area underlying the removed placenta. We therefore believe that the decidual material 
harvested contains mainly spiral arteries delivering blood to the placenta, and not the non-
transformed maternal arterioles from the membranous decidua. The method issue of 
harvesting is of some significance, since demonstration of spiral artery acute atherosis is one 
of the main issues in Paper IV. 
It has previously been demonstrated that removing decidual tissue by post partum 
curettage results in a more rapid normalization of the blood pressure and clinical condition 
of the preeclamptic patient (122). Staff et al have previously demonstrated that the vacuum 
suctioned decidual material obtained by this method yielded larger amounts of tissue than 
the traditional placenta bed biopsies (121). Our aim in Paper I was therefore to evaluate 
decidual tissue, collected using the vacuum suction method, for use in studies of decidual 
pathomorphology in preeclampsia and diabetes mellitus. For comparison, the same quality 
assessment was undertaken on archive material from placental bed biopsies (PBB) and 
placental basal plate sections (BPS). 
 One major advantage of the decidual suction method, compared to the placenta bed 
biopsy method, is the tissue yield (121), which makes it possible to undertake both 
morphological as well as molecular studies on the material collected. The higher amounts of 
tissue collected, as compared to placental bed biopsies, make this technique valuable for 
studying pathological conditions in the decidua, such as acute atherosis. Another advantage 
is that decidual tissue is collected from the whole uterine wall underlying the placenta, not 
only from small areas of the placenta bed. A further advantage of the vacuum suction 
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method is that it is easy and rapid to perform, and does not lead to short-term or long-term 
complications (Paper I) when performed by experienced members of staff. 
One of the disadvantages of the decidua suction method is the lack of topographical 
tissue orientation, in contrast to the placenta bed biopsy method in which the tissue 
orientation is well conserved. Another disadvantage is the relative lack of tissue from the 
myometrium (Paper I). Finally, the entire spiral artery is not presented in its whole length in 
the decidua suction method, which limits the interpretation of what is happening along its 
full length. 
In terms of studying acute atherosis of the spiral arteries, a phenomenon most often 
seen in the decidual spiral arteries, and seldom in the myometrial part (123), we believe the 
decidua suction method is superior, or at least complementary to the placenta bed biopsy 
method. The latter has significant limitations compared to the vacuum suction methods with 
respect to tissue yield and focal representation, as well as potential clinical complications 
such as uterine wall perforation and bleeding, necessitating uterine wall suturing. 
7.2.2  Acute atherosis  
In spiral arteries of the maternal decidua in the placental bed a set of related 
pathological changes are described as decidual vasculopathy. They include defect 
remodeling (physiological change), acute atherosis and mural or occlusive thrombosis. 
Acute atherosis is defined as accumulation of foamy macrophages in spiral arteries with 
areas of necrosis. Acute atherosis has been regarded a phenomenon of preeclampsia, 
although is not specific to it (124;125). The etiology and biology of acute atherosis is not 
well understood. One reason for this is the difficulty of finding spiral arteries in the decidua 
attached to the membranes or placental bed even under normal conditions. There are about 
100-150 spiral arteries in the placenta bed (70), and one is only able to harvest a very small 
proportion of them using a biopsy technique. Since the lesions in acute atherosis are focal 
(126), the phenomenon is technically difficult to study adequately. Much of the information 
on spiral artery changes comes from unique studies on intact hysterectomy specimens from 
early pregnancy (127). It has been argued that the hyperlipidemic profile in the maternal 
circulation in preeclampsia (84) may contribute to spiral artery lipid changes in the poorly 
transformed spiral arteries (128), resulting in a local endothelial dysfunction, which in turn 
contributes to the systemic disease. We found no evidence to support the validity of this 
theory for the entire group of preeclamptic women, since there was not significant 
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association between the local spiral artery acute atherosis and maternal lipid changes, or 
evidence of oxidative stress in the maternal circulation (Paper IV).  
Additionally, the severity of preeclamptic disease, as measured by premature 
delivery or a more elevated blood pressure, did not differ between the preeclampsia groups 
with or without acute atherosis (Paper IV). As acute atherosis is focal and does not occur in 
all spiral arteries (124) there might be a sampling bias. In the absence of thrombosis they 
may not have a major impact on the total uteroplacental circulation and fetal growth. 
 In our decidual placental bed material we also lack the spiral arteries from the 
myometrium. This might be another sampling bias, as some authors believe that focal 
decidual changes have no major effect on the maternal circulation (124;129).  
As we measured the presence of acute atherosis, we also made a quantification of the 
percentage of the transversal section of the vessel wall with CD68 positive foamy 
macrophages present. This was to investigate if there could be an association between a high 
level of CD68 positive foam cells in the spiral artery wall and the severity of the 
preeclamptic disease. We found no such association, however (Paper IV).
An interesting additional finding was the observation of CD68 positive foam cells 
and fibrinoid replacement in the subendothelial compartment of decidual arteries in 14% of 
non-preeclamptic patients in whom arteries could be identified (Paper IV). There are very 
few data on the exact nature of fibrinoid within the spiral artery wall, and further work on 
spiral artery fibrinoid replacement and fibrinoid necrosis is clearly necessary. PAS staining 
is a marker for matrix glycoproteins and “fibrinoid replacement”, and these areas 
surrounding the lipid-laden foam cells may possibly represent secretion products from the 
trophoblast cells replacing the muscular wall, and do not equal “fibrinoid necrosis” 
morphologically. The term fibrinoid necrosis is believed to be an expression of cell death in 
the spiral artery wall and is usually demonstrated in arteries exposed to hypertension. The 
phenomenon of acute atherosis is defined as presence of CD68 positive foam cells plus the 
presence of fibrinoid necrosis (130;131). Fibrinoid necrosis was not demonstrated in the 
uneventful pregnant women with presence of CD68 positive foam cells, and could therefore 
not be defined as true acute atherosis. For all the four women, in whom the CD68 positive 
foam cells were present in the spiral artery walls, there were no clinical or biochemical pre-
pregnant or intra-pregnant manifestations of disease and also no indication of restricted fetal 
growth in these pregnancies. It is possible to speculate that this group of uncomplicated 
pregnant women could have an unrevealed risk of cardiovascular disease later in life, and 
our biobank concept will allow us, or other associates, to study this on a long-term basis. 
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7.3 Methods for analyzing oxidative stress and antioxidant indices 
7.3.1 Isoprostanes 
As presented briefly in the introduction, there are several variables indirectly 
quantifying oxidative stress. As a measure of oxidative stress, we chose to measure the lipid 
peroxidation product 8-isoprostane, which is viewed as the “golden standard” for measuring 
oxidative stress (132), being more stable in terms of not undergoing further oxidative 
processes ex vivo, as long as the blood samples are treated adequately (adding indometacin 
to avoid platelet excretion of 8-isoprostane as well as butylated hydroxytoluene (BHT), a 
free radical scavenger, to avoid ex vivo formation of 8-isoprostane) (87). Gas 
chromatography mass spectrometry (GC-MS) is regarded as the superior method of 
analyzing 8-isoprostane, as it is highly specific and sensitive, though a complex and 
expensive method (132;133). It is also possible to measure the 8-isoprostane concentration 
with commercially available enzyme-linked immunosorbent assay (ELISA) kits, which are 
both inexpensive and measure 8-iso-prostaglandin relatively quickly, but this method cannot 
be regarded as a valid substitute for the more precise GS-MS assay (134).  
The isoprostanes are stable products of free radical-catalyzed peroxidation of 
arachidonic acid in cell membrane phospholipids (135). 8-iso-prostaglandinF2D (8-
isoprostane) is one of the isoprostanes most often used for analysis; it is excreted in urine 
and its half-life is 20 minutes. The ratio of free (not cell-bound to phospholipids) to total 8-
isoprostane (free and cell-bound 8-isoprostane) is 1:4 (132). The reason why we measured 
total, and not free, plasma 8-isoprostane in our studies (Papers II, III and IV), is because the 
concentration of total 8-isoprostane is higher than the free form and thereby easier to detect. 
This was therefore recommended by our collaborating laboratory in the UK (132). 
8-isoprostane can be detected in biological samples such as plasma, tissues and urine 
(136), and increased concentrations have been found in conditions associated with oxidative 
stress (136). Increased levels of circulating oxidative stress have been demonstrated in 
cigarette smokers, but intervention with vitamin E has not shown any positive effect in 
reducing excretion of urine 8-isoprostane (137;138). In our study (Paper II), we could have 
measured urine 8-isoprostane instead of plasma 8-isoprostane, but as preeclampsia may 
possibly affect renal function, and thereby urine excretion of isoprostane, we considered 
plasma samples to be preferable. 
In Papers II, III and IV, the blood samples from the patients were all collected and 
stored equally, the assays were performed equally and in a blinded manner, i.e. the 
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diagnoses were unknown to the technicians performing the assays. As blood samples were 
handled strictly according to the procedures, we believe that the difference in circulating 8-
isoprostane levels found between the preeclampsia group and the control group in Paper II, 
and also the lack of difference in the fetal circulation between the preeclampsia group and 
the control pregnancies in Paper III, reflects the existence of maternal augmented oxidative 
stress present in the circulation in preeclampsia, as well as no true difference in the fetal 
circulation, as compared to uncomplicated pregnancies. However, there are reports 
indicating that there is not always a good correlation between various methods measuring 
oxidative stress in the circulation, evaluated as lipid peroxidation products (139), therefore 
other methods might conclude differently. Also, patient selection might impact on the 
results, as shown by a negative finding of oxidative stress by Barden et al in the maternal 
circulation (79), using the same 8-isoprostane methodology as in our papers. 
 The interpretation of the 8-isoprostane results is open to challenge, since the groups 
are not matched for gestational age. However, it has previously been demonstrated that the 
plasma 8-isoprostane concentration in uneventful pregnancies remains unaltered throughout 
pregnancy (140), which could indicate that the elevated 8-isoprostane concentration in the 
preeclampsia group (compared to the uneventful pregnancy group, Paper II) represents a 
true elevation for the preeclampsia group, and is not merely a result of a lower gestational 
length. One might, in fact, speculate that there could have been an even more pronounced 
difference in 8-isoprostane concentration if the preeclampsia group had been compared with 
a group of gestationally matched uneventful pregnancies. Severity of preeclamptic disease, 
as indicated by premature delivery prior to gestational week 34 (n=13), was associated with 
elevated median maternal 8-isoprostane concentrations compared to the preeclampsia group 
(n=8) delivered after 34 weeks gestation (465 pg/mL and 236 pg/mL, respectively, P=0.01). 
The apparent “gestational“-decline in 8-isoprostane concentrations in preeclampsia in our 
study (Paper II) is most likely to be confounded by the severity of disease. It is the latter 
which is the indication for cesarean section (and thereby, the blood sampling time), whereas 
late delivered (and late onset) preeclamptics are not delivered prematurely since the disease 
is not severe.
 Few papers have previously been published regarding fetal isoprostane levels, and 
since different methods (such as ELISA or GC/MS) have been used, the results are difficult 
to compare. Also, the publications do not always indicate whether free or total 8-isoprostane 
concentrations are measured (141-144). A recently published study by Weinberger et al 
(145) report comparable results as we do in Paper III regarding plasma umbilical artery 
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concentrations of total 8-isoprostane in control infants (204 pg/ml measured with ELISA vs 
our result of 276 pg/ml measured with GC/MS, Paper III). The demonstration of a much 
higher concentration of 8-isoprostane in umbilical vein plasma compared to umbilical artery 
plasma in our study (Paper III), suggests that the placenta, and not the fetus, is the main 
source of fetal circulating 8-isoprostane, but such a difference between umbilical artery and 
vein 8-isoprostane was not found by Weinberger et al (145). 
 Exploring both the umbilical artery and the umbilical vein separately is beneficial in 
evaluating placental and fetal contribution to cord blood substances. Since some studies do 
not define whether mixed cord blood or separated cord blood is investigated, the results of 
the different publications are difficult to compare. However, the difference in concentrations 
of a substance between vein and artery cord blood gives an indication of whether there is a 
net uptake or production in the fetus. The venous umbilical cord blood mainly represents 
placenta derived blood to the fetus, whereas the arterial umbilical blood concentrations 
possibly better reflects the fetal situation, as the blood is circulated from the fetus towards 
the placenta. There are, though, technical challenges in collecting separated umbilical and 
vein cord blood, since especially the premature umbilical arteries are often fragile and 
constricted and difficult to handle as well as containing restricted volumes of arterial blood. 
The restricted volume is the reason for not having performed d-ROM analyses in the fetal 
circulation (Paper III), only in maternal circulation (Paper II). In addition, less fetal than 
maternal samples were available, therefore fewer patients were included in Paper III 
(requiring fetal samples) as compared to Paper II.  
7.3.2 Antioxidant indices 
Antioxidant capacity (AC) is defined as the measure of the moles of a given free 
radical scavenged by a test solution, independently of the antioxidant activity of any one 
antioxidant present in a given mixture (146). It is also regarded as a representative measure 
of the true balance between reactive oxygen species and antioxidant defense (146). Various 
methods have been developed for measuring total antioxidant status, but there is no 
accepted general reference method, nor one specifically for analyses in pregnancy. Widely 
used methods for measuring reactive oxygen species include colorimetric, fluorescence, 
chemiluminescence and electron spin resonance spectroscopy, but most methods are time-
consuming, expensive, need sophisticated techniques and are not available in a routine 
laboratory (147). The total radical-trapping antioxidant parameter (148) is regarded as 
reliable, but is time consuming and has to be analyzed immediately with fresh plasma (149). 
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Oxygen radical absorbance capacity (ORAC) and Randox Trolox-equivalent antioxidant 
capacity (Randox-TEAC) assays are also commonly used measures of AC in the circulation 
(150). Unfortunately, in general the assays do not correlate with each other. Several of the 
assays have been applied to preeclampsia, with results varying from no change (97) to 
increases (151) and decreases (152) in plasma/serum antioxidant capacity compared to 
normal pregnancy. This is partly because the antioxidant capacity result depends upon 
which free radicals or oxidants are used in the measurements (153).  
The method used in Paper II and III for measuring AC is the controversial ferric 
reducing ability of plasma (FRAP). The FRAP assay is one of several methods developed to 
assess the “total antioxidant capacity” of serum or plasma. It is a more recent method and it 
has (to our knowledge) not been used as a measure of AC in pregnancy before. The FRAP 
assay is regarded as highly reliable; it requires low blood volume, is not time-consuming 
and it is cheap (154).
The major objection against FRAP measurement in preeclampsia is the influence on 
the assay of uric acid (a potent antioxidant). This aspect is thoroughly discussed in Paper II 
and III, as well as in a discussion following the publication of Paper III (155). The role of 
uric acid in preeclampsia remains to be established: whether it actually exerts a net 
antioxidant effect, whether it has a role in the development of the syndrome or merely 
represents a marker of disease severity (156).
The d-ROM (reactive oxygen metabolites) test offers a complementary approach to 
the measurement of the total antioxidant capacity to evaluate the redox status, measuring 
ROM in serum. The test is regarded as both stable and precise, as well as being a 
reproducible method for the quantitative evaluation of oxidative stress (157). The method is 
discussed in Paper II, but was not used as a method in analyzing the fetal blood samples in 
Paper III due to limited blood volume. We have no reason to believe that the d-ROM test or 
the FRAP assay are superior markers, compared to other methods of analyzing AC, but they 
represent an additional approach to this difficult field of analysis. 
 The impact of the severity of preeclamptic disease, as indicated by premature 
delivery prior to gestational week 34, or defined according to the ACOG criteria, was 
investigated for FRAP or d-ROM in Paper II, demonstrating no statistical significant 
difference in FRAP- or d-ROM levels. We demonstrated unaltered vitamin E concentrations 
in maternal circulation in preeclampsia (Paper II), in agreement with some reports (158), but 
in contrast to others (38;159), as discussed in Paper II. For the fetal circulation, we believe 
that umbilical artery samples better reflect the fetal situation than the umbilical vein 
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samples. Therefore, we interpret our findings in Paper III of elevated concentration of 
vitamin E in umbilical vein and unaltered in umbilical artery for the preeclampsia group (as 
compared to the control group), as evidence for unaltered vitamin E concentration in the 
fetal circulation in preeclampsia. As discussed in Paper III, we only found one previous 
publication regarding vitamin E level in infants in preeclampsia, and the results were in 
accordance with our own (97).  
7.4 Statistics
As not all the values in Papers II-IV were normally distributed, median and 95% 
confidence intervals of the median are reported. The Mann-Whitney U-test was used for 
testing differences between groups. Pearson’s or Spearman’s correlation was used to 
calculate correlation coefficients. Statistical analyses were performed using Statistical 
Package for the Social Sciences (SPSS) version 10 (Paper I) and version 11 (Papers II-IV). 
We did not perform detailed sample size analyses prior to the start of the sub-studies, 
as not all study variables had been analyzed previously, and we were therefore not aware of 
standard deviations. Our studies could therefore be considered as pilot studies. We were 
interested in finding at least one standardized difference between the groups, considered 
clinically relevant to detect. According to Altman (160), we would need at least 30 women 
(15 pregnant women with preeclampsia and 15 controls) in order to detect such a difference 
with a significance level of 0.05 and a power of 80%. In future studies, our results could be 
used for calculations of sample size in order to ensure sufficient power to detect differences 
between study groups.
Finally, multiple statistical testing is performed in Papers II-IV. The recruited 
pregnant women in Papers I-IV come from the same biobank study (apart from some tissue 
specimens in Paper I), hence methods such as Bonferroni’s could have been used to avoid a 
type 1 error (incorrectly declaring a difference). We did not undertake a Bonferroni 
correction of the p-value level since we explored distinct hypotheses in each paper, each 
with different tests based on biologically plausible hypotheses. A Bonferroni correction 
would entail a loss of power and we might thus incorrectly not have detected a difference 
(type 2 error). Since there are correlations between the outcome variables, a Bonferroni’s 
correction is considered too conservative in such as situation (161). 
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8. Conclusions 
1. The placental bed vacuum suction method represents a significant improvement in 
obtaining relevant and sufficient decidual tissue for morphological, functional and 
molecular studies of extravillous trophoblasts, spiral artery morphology and other 
components of decidual tissue from the placental bed (Paper I). The method is superior to 
placental bed knife biopsies and tissue sections from placental basal plate. 
2. The placental bed vacuum suction method can be used for studies of acute atherosis in 
spiral arteries in the decidual tissue in preeclamptic, diabetic and uncomplicated pregnancies 
(Paper I and IV).  
3. Increased oxidative stress, measured as 8-isoprostane (Paper II and III) was found in the 
maternal circulation in preeclampsia, but not in the fetal circulation, compared to 
uncomplicated pregnancies. The concentrations of 8-isoprostane were higher in the 
umbilical vein than in the umbilical artery, indicating placental, rather than fetal, origin of 
this substance. The antioxidant capacity was elevated in the preeclampsia group in both the 
maternal and fetal circulation (measured as elevated FRAP, Paper II and III). On the other 
hand, another antioxidant index, d-ROM, was unaltered in maternal circulation (Paper II) 
and vitamin E was unaltered both in maternal (Paper II) and fetal circulation (Paper III).
4. The elevated maternal concentration of the angiogenic factor sFlt1 in preeclampsia was 
associated with augmented oxidative stress, measured as 8-isoprostane concentrations 
(Paper II). 
5. Presence of acute atherosis in decidual spiral arteries was not necessarily paralleled by 
maternal augmented oxidative stress or hyperlipidemia, neither in preeclamptic nor in 
uneventful pregnancies (Paper IV).
In conclusion, pregnancies complicated by preeclampsia demonstrate large heterogeneity, 
both with regard to presence of augmented oxidative stress and placental pathology, such as 
acute atherosis. Even if both phenomena occur more frequently in preeclampsia than in 
uncomplicated pregnancies, they are not necessarily present simultaneously or in similar 
magnitude. Preeclampsia is a potentially life-threatening disease for mother and child, and 
does not seem to have one simple underlying cause, valid for all women developing the 
syndrome. Further research and understanding of the pathophysiology are required before 
there can be successful trials on intervention and prevention of the syndrome.  
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9. Future Projects 
 Our ongoing collection of biobank-samples from complicated and uncomplicated 
pregnancies at Ullevål University Hospital will enable us to continue our research on 
maternal-placental and fetal interactions and the pathophysiology of preeclamptic and 
diabetic pregnancies. Our sampling methods allow us to investigate various 
pathophysiological aspects concomitantly, both in diabetes and preeclampsia research 
projects.
 We have several potentially interesting collaboration projects for future work, where 
inclusion of clinically well-defined patient populations is essential, as well as a thorough 
biobank sampling of extensive biological material from each participating subject. The 
biobank studies led by principal supervisor, Associate Professor Annetine Staff, will 
continue after the termination of my PhD period, and I intend to contribute to future studies, 
combining clinical and basic research methods. 
1. Renin Angiotensin System (RAS)
In a collaboration with a research group in Berlin, led by researcher Ralf Dechend, we have 
recently been able to demonstrate novel aspects of the RAS system being linked to 
preeclampsia, including presence of the circulating agonistic AT1 receptor autoantibodies 
(AT1-AA) in the fetus of preeclamptic pregnancies (118). In the future, we wish to explore 
further the function of RAS in preeclampsia, and also possible short-term and long-term 
consequences for fetal and maternal health.  
2. The DIP study (decidual immunological disturbance)
Normal cellular interaction in pregnancy and knowledge of changes in the 
placental/decidual cellular interactions in women with preeclampsia are of pivotal 
importance in our understanding of pregnancy-related diseases. In this DIP study, a 
collaboration with the principal researcher Mette Holthe, we will compare distribution of 
local immune cells in decidual/placental tissue in preeclampsia and pregnancies using flow 
cytometry and vacuum suction collected decidual tissue. We will also compare circulating 
immune cells with decidual tissue immune cells and immune responses in preeclampsia and 
uncomplicated pregnancies. 
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3. Functional studies of placenta lipid transport proteins   
In collaboration with researchers Kari Anne Risan Tobin, Guro M. Johnsen and Asim Dutta-
Roy at the Department of Nutrition and Institute of Basic Medical Sciences, University of 
Oslo, we are currently exploring the roles of lipid droplet associated proteins, including 
ADRP (Adipose Differentiation Related Protein), the overall goal being to describe their 
role in the placenta. These studies will include isolation of human trophoblast cells, 
molecular studies and immunohistochemistry of decidual tissue sections from our biobank. 
4. Diabetic pregnancies and decidual pathology
In collaboration with Professor Borghild Roald at the Department of Pathology at Ullevål 
University Hospital, we will compare placental and decidual findings to circulating markers 
of disease (such as angiogenic factors) in diabetic pregnancies as compared to 
uncomplicated pregnancies.  
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